HS
CLDX icon

HighVista Strategies’s Celldex Therapeutics CLDX Stock Holding History

HighVista Strategies’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.24M Sell
86,964
-2,433
-3% -$78.6K 0.74% 41
2026
Q1 		$2.84M Buy
89,397
+37,592
+73% +$1.02M 0.78% 43
2025
Q4 		$1.41M Sell
51,805
-83,453
-62% -$2.2M 0.36% 75
2025
Q3 		$3.5M Buy
135,258
+28,705
+27% +$665K 0.86% 31
2025
Q2 		$2.17M Buy
+106,553
New +$2.07M 0.8% 38
2024
Q4 		– Sell
-8,981
Closed -$305K – 148
2024
Q3 		$305K Sell
8,981
-646
-7% -$24.6K 0.11% 142
2024
Q2 		$356K Buy
+9,627
New +$363K 0.13% 127
2023
Q4 		– Sell
-17,482
Closed -$481K – 129
2023
Q3 		$481K Sell
17,482
-7,260
-29% -$228K 0.22% 113
2023
Q2 		$839K Hold
24,742
– – 0.38% 61
2023
Q1 		$890K Hold
24,742
– – 0.73% 41
2022
Q4 		$1.1M Sell
24,742
-684
-3% -$24.4K 0.65% 38
2022
Q3 		$715K Buy
25,426
+3,014
+13% +$92.4K 0.41% 69
2022
Q2 		$604K Sell
22,412
-3,326
-13% -$96.6K 0.36% 69
2022
Q1 		$877K Sell
25,738
-4,118
-14% -$132K 0.56% 48
2021
Q4 		$1.15M Buy
29,856
+1,390
+5% +$60.6K 0.92% 34
2021
Q3 		$1.54M Sell
28,466
-5,427
-16% -$255K 1.02% 18
2021
Q2 		$1.13M Buy
33,893
+953
+3% +$26.2K 0.8% 18
2021
Q1 		$678K Sell
32,940
-16,915
-34% -$388K 0.5% 44
2020
Q4 		$873K Buy
49,855
+5,026
+11% +$90.5K 0.56% 38
2020
Q3 		$665K Buy
+44,829
New +$525K 0.48% 23

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighVista Strategies's CLDX Position: Q2 2026 in Review

HighVista Strategies reduced its Celldex Therapeutics (CLDX) stake by 2.7% in Q2 2026, selling an estimated $78.6K and leaving 86,964 shares worth $3.24M. The position accounts for 0.74% of the portfolio, ranked #41.

HighVista Strategies first reported a position in CLDX in Q3 2020 and has held it in 20 quarters since. The position peaked at $3.5M in Q3 2025. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • HighVista Strategies held 86,964 shares of Celldex Therapeutics worth $3.24M as of Q2 2026.
  • HighVista Strategies sold 2,433 Celldex Therapeutics shares in Q2 2026, an estimated $78.6K.
  • Celldex Therapeutics made up 0.74% of HighVista Strategies's portfolio in Q2 2026, its #41 holding.
  • HighVista Strategies first reported a position in Celldex Therapeutics in Q3 2020 and has held it in 20 quarters since.
  • HighVista Strategies's Celldex Therapeutics position peaked at $3.5M in Q3 2025.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.